Cases
ARIAD Pharmaceuticals (NASDAQ: ARIA)
Securities Class Action
Overview
Overview
- Date:
- 2/2/2017
- Company Name:
- ARIAD Pharmaceuticals
- Stock Symbol:
- ARIA
- Class Period:
- FROM 1/28/2017
- Status:
- Closed/Complete
- Court:
- U.S. District Court: Massachusetts
NEW YORK, February 2, 2017 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who held ARIAD Pharmaceuticals (NASDAQ: NSR) securities on January 28, 2017 (the “Class Period”).
On January 9, 2017, the two parties announced the signing of a definitive merger agreement pursuant to which Takeda Pharmaceutical Company Limited will acquire ARIAD Pharmaceuticals in a deal worth $5.2 billion. As a result of the merger, ARIAD shareholders are only anticipated to receive $24.00 in cash for each share of ARIAD common stock.
The complaint alleges that the company failed to conduct a fair sales process and failed to disclose all material information regarding the sale of the company.
If you held ARIAD securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On January 9, 2017, the two parties announced the signing of a definitive merger agreement pursuant to which Takeda Pharmaceutical Company Limited will acquire ARIAD Pharmaceuticals in a deal worth $5.2 billion. As a result of the merger, ARIAD shareholders are only anticipated to receive $24.00 in cash for each share of ARIAD common stock.
The complaint alleges that the company failed to conduct a fair sales process and failed to disclose all material information regarding the sale of the company.
If you held ARIAD securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.